Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
about
T cell avidity and tumor recognition: implications and therapeutic strategies.Genetic engineering with T cell receptorsSialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responsesRedirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.T cell receptor-transgenic primary T cells as a tool for discovery of leukaemia-associated antigens.Gene transfer of human TCR in primary murine T cells is improved by pseudo-typing with amphotropic and ecotropic envelopes.Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens.Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection.Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma.Magnetic-activated cell sorting of TCR-engineered T cells, using tCD34 as a gene marker, but not peptide-MHC multimers, results in significant numbers of functional CD4+ and CD8+ T cellsGenetically engineered T cells for the treatment of cancer.Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and miceTreating cancer with genetically engineered T cells.Phenotypic and Functional Properties of Human Steady State CD14+ and CD1a+ Antigen Presenting Cells and Epidermal Langerhans CellsRecent advances in tumour antigen-specific therapy: in vivo veritas.Exploiting T cell receptor genes for cancer immunotherapy.Engineering T cells for cancer therapy.The past, present, and future of adoptive T cell therapy.High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor.T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy.T-cell receptor gene therapy for cancer: the progress to date and future objectives.An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8α Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT.An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells.Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacitiesMolecular immunology lessons from therapeutic T-cell receptor gene transfer.Adoptive immunotherapy for cancer.TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced to CD8+ T cells.Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer.A Molecular Switch Abrogates Glycoprotein 100 (gp100) T-cell Receptor (TCR) Targeting of a Human Melanoma Antigen.Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice.Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo.TCR mispairing in genetically modified T cells was detected by fluorescence resonance energy transfer.The potency of allospecific Tregs cells appears to correlate with T cell receptor functional avidity.Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer.
P2860
Q24815775-5DF2DEB9-F457-466D-B9A7-98CE8AD775B7Q26995677-F652BB03-5AB7-4516-8844-AAFB2ECD4A93Q30367426-7426A515-4662-4D8E-91C2-72988C219744Q33208099-5B4C94E1-1BA4-40A0-BE47-C275FD95AC8CQ33230010-9F32C789-73C9-44E8-8F9F-A226344AA0EEQ33283311-8B498B48-AF1C-4569-814D-B0434CEAAC3BQ33526549-4C1F1CCA-743C-44C4-B8ED-8D9600CE00EDQ33530527-DB1A3DEC-AA48-47F6-8C2A-1825FB953938Q33613320-F7758697-C3BE-4FA3-BA2D-C30B15D7C5CAQ33691970-9C509E36-F5EB-48EB-928B-361216261E07Q33841127-1DA6E28C-35B3-45EF-A078-DBF0214463D0Q34102273-75370A28-DCE5-4AE7-BE4C-9ED46732D809Q34370215-FEA46783-7E33-4964-AA80-CE1D5438390EQ34645898-3B46A6C1-0724-40E8-82C8-1C39532844E4Q34669675-A25ABE3A-FC96-4C16-8CC2-6EB50FEA777BQ35142813-BE39F6C1-45CD-493D-B8A0-C5C6FC34360AQ35353365-8E2F7407-5734-4165-BDD3-20195B3DA062Q35852261-91B5DA9C-AA41-40C8-89BE-EAAC3FF69E6AQ35896209-A83404A5-331E-407A-A4F2-C22E196ACAC3Q36011784-EBC08964-DDDD-45A9-9182-E9E3AFE6EBAEQ36298319-CAB5083F-F825-44A2-8023-D1DF9839B59BQ36306644-BDAD5384-EA10-4607-A5A2-596DD7750BBDQ36471584-5215672C-855C-4266-9646-0937E80528D3Q36664207-B8129F80-434D-4459-81F5-1909A122244EQ36842738-BC902AD9-9810-4A65-BCEF-BCE65A43D1FAQ36909378-749369A6-FDA1-463F-A47D-C2C25A2A419AQ37145706-2A4E7C0B-DE8C-4102-A325-E51D201B61CFQ37225251-2F6F5196-38B1-4013-9E83-D45770E2DB04Q37741606-82072434-313E-40CF-ABC4-22114B7ABBEAQ37766303-A8BB21A7-2A1D-4A83-B7B7-6EA7EBD66672Q38170496-11EF886D-207B-45F4-9F22-DE4E91C6EAFDQ39383424-7A362245-50B7-468E-85DF-3AFB10D9616BQ40010912-6BAB00E0-78F5-425E-A735-2AC5EBBB58E5Q40572007-F346A6DF-1767-470E-9629-A2ED9144F9BFQ40776677-1BA71377-F726-4A4E-89D1-58A91B5FF157Q42915120-2BAF3593-BA5E-4A9B-B119-D4265DE171C2Q43238571-2C958230-C814-45CD-A562-0D4F43C4A20BQ44362708-A3650668-AB57-4619-95EF-FEAD28E8C189Q44781094-290A18DF-4D25-4E40-A6C8-83275C039C5BQ45857062-70641017-F82B-4D05-B3D4-54B2E4AA0195
P2860
Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Peptide fine specificity of an ...... o primary human T lymphocytes.
@ast
Peptide fine specificity of an ...... o primary human T lymphocytes.
@en
type
label
Peptide fine specificity of an ...... o primary human T lymphocytes.
@ast
Peptide fine specificity of an ...... o primary human T lymphocytes.
@en
prefLabel
Peptide fine specificity of an ...... o primary human T lymphocytes.
@ast
Peptide fine specificity of an ...... o primary human T lymphocytes.
@en
P2093
P1476
Peptide fine specificity of an ...... o primary human T lymphocytes.
@en
P2093
Birgit Lankiewicz
Bram W L Essers
Carl G Figdor
Gosse J Adema
Jan-Willem Gratama
Jolanda de Vries
Niels Schaft
Ralph A Willemsen
Reinier L H Bolhuis
Reno Debets
P304
P356
10.4049/JIMMUNOL.170.4.2186
P407
P577
2003-02-01T00:00:00Z